Saco J. de Visser

Centre For Development Studies — India

Economics, Econometrics and Finance · Social Sciences

15h-index1.2kcitations42works3.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Health Systems, Economic Evaluations, Quality of Life(14), Pharmaceutical Economics and Policy(12), Genomics and Rare Diseases(4), Neural and Behavioral Psychology Studies(3), Neurotransmitter Receptor Influence on Behavior(3)

Publications42 total

Medicine Development and Access for Rare Diseases: Can We Do Better?
Journal of Inherited Metabolic Disease·2026Open Access
Repurposing biosimilars, rethinking costs: a framework for sustainable drug pricing for repurposed bevacizumab for intravitreal injections
The European Journal of Health Economics·2026Open Access
Tracing the path of non-industry-driven medicine development for rare diseases through regulatory interactions at the European Medicines Agency
Drug Discovery Today·2026Open Access
Low‐dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug–drug interaction study
British Journal of Clinical Pharmacology·2025Open Access
Guiding the willingness to pay for repurposed tiratricol in the treatment of Allan-Herndon-Dudley syndrome using a cost-based-plus pricing framework
2025Open Access
Application of four pricing models for orphan medicines: a case study for lumasiran
Orphanet Journal of Rare Diseases·2024· 2 citedOpen Access
Editorial: Towards continued and affordable accessibility of innovative drugs: sustainable development and efficient use of medicines
Frontiers in Pharmacology·2024Open Access
Drug pricing models, no ‘one-size-fits-all’ approach: a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape
The European Journal of Health Economics·2024· 15 citedOpen Access
Question-based drug development and the value of novel treatments
Expert Review of Pharmacoeconomics & Outcomes Research·2024Open Access
Cannabidiol Increases Psychotropic Effects and Plasma Concentrations of Δ<sup>9</sup>‐Tetrahydrocannabinol Without Improving Its Analgesic Properties
Clinical Pharmacology & Therapeutics·2024· 15 citedOpen Access
From setbacks to success: lessons from the journey of RSV vaccine development
Therapeutic Advances in Vaccines and Immunotherapy·2024· 2 citedOpen Access
Development of medicines for rare diseases and inborn errors of metabolism: Toward novel public–private partnerships
Journal of Inherited Metabolic Disease·2023· 9 citedOpen Access
Access to medicines for rare diseases: A European regulatory roadmap for academia
Frontiers in Pharmacology·2023· 11 citedOpen Access
Drug Repurposing for Rare Diseases: A Role for Academia
Frontiers in Pharmacology·2021· 49 citedOpen Access
Author Reply
Value in Health·2021Open Access
Cost-Based Price Calculation of Mexiletine for Nondystrophic Myotonia
Value in Health·2021· 40 citedOpen Access
A novel sustained‐release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers
Pharmacology Research & Perspectives·2021· 6 citedOpen Access
The pharmaceutical research and development productivity crisis: can exploratory clinical studies be of any help?
Elsevier eBooks·2021
List of contributors
Elsevier eBooks·2021
Registries for orphan drugs: generating evidence or marketing tools?
Orphanet Journal of Rare Diseases·2020· 26 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Joop van Gerven(14), Adam F. Cohen(11), Carla E. M. Hollak(11), Sibren van den Berg(9), Rik C. Schoemaker(8), Vincent van der Wel(6), J. P. Van Der Post(5), AF Cohen(5), Ingrid M. C. Kamerling(5), Evert A. Manders(5), Jacobus Burggraaf(4), Noa Rosenberg(4), M. S. M. Pieters(3), Meta Roestenberg(3), Nina N. Stolwijk(3), Sanne Lysbet de Haas(2), M. Gail Murphy(2), M. De Smet(2), B. Rijnbeek(2), Joris van der Post(2)